In Vitro Fertilization Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global In Vitro Fertilization Market Trends and Insights

Rising Infertility Prevalence and Diagnosis Rates

Roughly 17.5% of adults now face infertility, a rise from 15% in 2010, according to a 2025 World Health Organization update ^{[1]World Health Organization, “1 in 6 People Globally Affected by Infertility,” who.int}. Improved diagnostic coverage uncovers previously hidden cases, especially in India, where district hospitals added infertility screening under the National Health Mission in 2024. In the United States, 13.4% of women aged 15-49 experienced impaired fecundity in 2024, up from 12.1% in 2015, amid higher obesity rates and endocrine-disruptor exposure ^{[2]Centers for Disease Control and Prevention, “Infertility FAQs,” cdc.gov}. The in vitro fertilization market benefits because diagnosed patients are more likely to pursue treatment. Clinics respond by scaling laboratory capacity and frozen-storage infrastructure to absorb volume. As stigma eases and subsidies rise, pent-up demand continues to convert into active treatment cycles, lifting procedure counts in developing economies.

Increasing Average Maternal Age at First Birth

Mean maternal age at first birth reached 28.2 years in the United States in 2023 and climbed to nearly 30 years in several OECD members, a demographic tilt that inflates cycle volumes because older patients require more attempts for success. Japan reported that 29.8% of first births occurred to mothers aged 35 or older in 2024, prompting subsidy ceilings to rise to JPY 300,000 (USD 2,000) per cycle. Clinics, therefore, diversify stimulation protocols, offering mini-IVF to manage diminished ovarian reserve while protecting live-birth outcomes. The in vitro fertilization market embeds these age-driven treatments as core growth, particularly in East Asia and Southern Europe, where delayed childbearing is widespread. Equipment makers emphasize gentle stimulation monitoring tools to attract this expanding demographic.

Technological Leaps in Cryopreservation & Culture Media

Vitrification success rates now exceed 95%, allowing elective single-embryo transfer that minimizes multiple-pregnancy risk. FUJIFILM Irvine Scientific launched a culture medium in 2024 featuring hyaluronan and recombinant albumin that improved blastocyst formation by 7% in multi-center trials. Time-lapse incubators give embryologists uninterrupted morphokinetic data, enhancing embryo grading accuracy and standardizing lab outcomes. Rapid tech diffusion narrows performance gaps between academic centers and community clinics, widening the addressable base for premium consumables. As a result, the in vitro fertilization market records consistent cycle success and attracts private-equity investment into scalable clinic chains.

Expansion of Cross-Border Fertility Tourism Networks

An estimated 35,000 European patients traveled for cross-border IVF in 2024, chiefly from Germany, Italy, and France to Spain and the Czech Republic, to secure anonymous donor gametes at lower cost. Thailand saw a sharp increase in fertility-tourism arrivals from Australia and the Middle East, amplifying demand for English-language counselors and tele-consult platforms. Destination clinics invest in remote monitoring so patients can complete preliminary workup at home, reducing travel to two visits. The trend pressures restrictive jurisdictions to liberalize policies to stem outbound spend, illustrated by Germany’s 2025 consultation on legalizing egg donation. These patient flows diversify geographic revenue streams for suppliers, supporting the in vitro fertilization market across multiple hubs.

High Treatment Cost and Patchy Insurance Reimbursement

A single IVF cycle in the United States costs USD 15,000–30,000, and patients average 2.5 cycles for a live birth, leaving uninsured couples liable for USD 37,500–75,000. Only 21 states mandate partial coverage, often with age caps or cycle limits, which delays treatment start. In India, an INR 150,000 (USD 1,800) price tag equals 4 months of urban household income, making affordability a major barrier. Clinics experiment with mini-IVF protocols that cut medication costs by 40%, yet lower success per cycle may neutralize savings. High prices, therefore, dampen uptake in cash-pay markets and cap the in vitro fertilization market in low-income regions.

Supply-Chain Vulnerability in Specialty Reagents & Plastics

Red Sea disruptions in 2024 delayed media shipments to Asia-Pacific clinics by up to 5 weeks, forcing schedule alterations and fresh-cycle postponements. Culture media depend on purified proteins sourced from a few suppliers, creating a single-point failure risk. Plastics prices swing with crude oil volatility, inflating catheter costs by up to 20% within a year. FUJIFILM Irvine Scientific and Vitrolife are building secondary plants in Singapore and the United States to hedge risk, but capacity will not come online until late 2026 ^{[3]FUJIFILM Irvine Scientific, “Business Continuity Announcements,” irvinesci.com} . Supply fragility, therefore, constrains near-term growth for the in vitro fertilization market.

Segment Analysis

By Product: Instruments Lead, Consumables Accelerate

In 2025, instruments generated 55.2% of revenue, illustrating capital intensity in IVF laboratories where incubators, micromanipulators, and laser systems dominate budgets. Vitrolife’s EmbryoScope time-lapse incubator, priced at USD 80,000–120,000, anchors this premium tier. Consumables & disposables, however, post the fastest 10.21% CAGR to 2031 as clinics shift toward single-use catheters under tighter sterility rules. The in vitro fertilization market size for consumables is projected to account for one-third of incremental revenue gains through 2031. Regulatory pressure to validate cleaning procedures for reusable equipment accelerates the switch to disposables, while private-equity investors favor the predictable reorder cycle attached to consumable sales. 

A broader push for contamination control drives demand for closed vitrification devices and pre-sterilized culture dishes. Hamilton Thorne integrates laser-assisted hatching into catheter tips, blending instrument functionality with recurring disposable income. Suppliers bundle service contracts and replacement parts to lock in clinics for five-year terms, creating high switching costs. As manufacturing scales, unit prices fall, enlarging adoption among mid-volume centers and sustaining the in vitro fertilization market.

Note: Segment shares of all individual segments available upon report purchase

By Cycle Type: Fresh Dominates, Donor Egg Surges

Fresh non-donor cycles retained 34.2% revenue in 2025 owing to patient preference for autologous gametes and lower lab fees versus donor options. Yet donor egg cycles rise at a 10.98% CAGR, the highest within this category, benefiting from legal liberalization in Japan and persistent demand among women over 40. In Spain, donor egg revenues hit EUR 180 million (USD 195 million) in 2024, fueled by cross-border inflows. The in vitro fertilization market share for donor eggs is projected to reach double-digits by 2031. 

Thawed-embryo cycles benefit from 95% post-vitrification survival, letting clinics adopt segmented stimulation strategies that minimize ovarian hyperstimulation risk. Cryobanks invest in genetic panels covering 300 inherited conditions, raising perceived quality and allowing premium pricing. Clinics that build or partner with egg banks secure supply and margin, while regulation remains a wild card as anonymity rules evolve across Europe and Asia-Pacific.

By Procedure Type: Conventional IVF Anchors, PGT/PGD Climbs

Conventional IVF delivered 33.4% of revenue in 2025, cementing its role for tubal-factor and unexplained infertility. Intracytoplasmic sperm injection (ICSI) now features in 70% of cycles globally, reflecting clinician preference for predictable fertilization rates despite higher consumable costs. IVF with PGT/PGD accelerates at a 10.11% CAGR, supported by Illumina’s sequencers that halve per-embryo testing cost to USD 200 in 2024. The in vitro fertilization market size attached to PGT could approach USD 5 billion by 2031 if reimbursement expands. 

Professional societies caution that PGT-A offers limited benefit in women under 35, prompting selective payer coverage. Still, older patients and couples with recurrent loss maintain a strong demand. Natera’s carrier screening routes at-risk couples into downstream PGT-M testing, reinforcing the revenue loop. Clinics differentiate by offering same-day biopsy turnaround, leveraging newer bench-top sequencers.

Note: Segment shares of all individual segments available upon report purchase

By End User: Fertility Clinics Dominate and Accelerate

Fertility clinics captured 61.45% revenue in 2025 and are on track to grow 11.3% yearly, the fastest among end users. Their focused operating model supports investment in AI grading, rapid genetic testing, and patient-experience apps. Hospitals remain important for complex surgical adjuncts but grow more slowly as administrators juggle broader service lines. Cryobanks and research labs, though smaller, underpin donor-gamete and innovation pipelines for the in vitro fertilization industry. 

Chain operators wield scale to negotiate consumable discounts and integrate back-office systems, while independents compete on concierge scheduling. IVI RMA Global reported 19% volume growth in 2024, driven by Latin-American expansion. Boston IVF adopted iDAScore network-wide in 2025, aiming to standardize outcomes. This consolidation raises entry barriers for new clinics but presents acquisition opportunities for investors seeking regional density.

Geography Analysis

North America delivered 43.1% of revenue in 2025, buoyed by 330,000 U.S. cycles performed in 2024 and expanding state mandates in California, Colorado, and New York. Employer-funded benefits and high disposable income sustain premium add-on adoption, including PGT and AI grading. Canada’s single-cycle provincial coverage drives early uptake, though many patients pay for subsequent attempts, supporting the in vitro fertilization market. Suppliers focus on regulatory compliance and bundled service contracts to protect their share amid competition from lower-priced imports.

Europe maintains steady growth as national health systems subsidize treatment and liberal gamete-donor laws attract cross-border patients. Spain and the Czech Republic serve as donor-egg hubs, and clinics leverage multilingual staff to capture demand. Germany’s 2025 consultation on legalizing egg donation could repatriate outbound spend. Regulatory alignment under the IVDR lengthens approval cycles for genetic-testing add-ons, yet once cleared, uniform rules simplify rollout across member states.

Asia-Pacific posts the highest 9.32% CAGR to 2031. China completed 530,000 cycles in 2024, up 22% year on year, after easing private-clinic licensing and broadening insurance coverage under urban employee plans. Japan’s JPY 300,000 (USD 2,000) subsidy stimulates uptake among women under 43, while India’s tier-2 cities witness rapid chain expansion targeting the middle class. Localization of culture-media production in Singapore and domestic catheter molding plants in China mitigates shipping delays and import duties, further energizing the in vitro fertilization market.